On Monday November 30th, the Rafael del Pino Alumni Association, with the support of the Rafael del Pino Foundation, was pleased to organize a dinner-colloquium with Mr Josep Pous, founder of Prous Institute and Prous Science (see complete profile below). Founded in 1958, Prous Science is a global leader in IT solutions for the life-science industry. Physicians and scientists worldwide use Prous Science products and services in the development of new drugs based on knowledge, safety and efficiency, improving global medical practices.
During the event, the Rafael del Pino Alumni had the opportunity to share with Dr. Prous his views on the current status of the biotech industry in Spain as well as the prospects for the biomedicine sector. Several experts of the pharmaceutical and biotech industries as well as MIT, Stanford, LBS, Wharton, Columbia and Chicago alumni attended the event.
Josep Prous Biography
After obtaining his PhD in Biochemistry , Dr Pous worked as researcher in the Pharmaceutical industry where he realized information about new drugs was scarce and spread among several publications. As a consequence of the discovery, the first product of Prous Science, the magazine “Drugs of Today” was created in order to inform about innovation in the development of new drugs.
Prous Science launched several successful products that incorporated the latest advances in information technologies such as Dailydrugnews.com life-science newsfeed and Integrity, the first integrated new drugs discovery and development website, with access to over 295.000 drugs and 100.000 patents.
With 350 employees, Prous Science is based in Barcelona and has expanded to US, Argentina and Japan. Prous Science has been awarded several prestigious international prizes including the European WWW Business Award by the European Commission. In 2007 Prous Science was acquired by Thomson Reuters
In 2000 Dr. Prous started a new endeavour in the Scientific Park of Barcelona, Prous Institute, a center for new drugs research using computational technologies for the treatment of cancer, diabetes or neurological conditions. Prous Institute is currently cooperating with the FDA in food and drugs toxicity prediction programs.